Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
RAPT Therapeutics, Inc. - Common Stock
(NQ:
RAPT
)
33.53
-0.14 (-0.42%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 21, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about RAPT Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
Today 16:01 EDT
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
October 20, 2025
Via
Benzinga
Rapt Therapeutics, Outperforming 98% Of All Stocks, Skyrockets After Topping Roche
October 20, 2025
The company took on Roche's Xolair in a 16-week study of patients with a chronic hives disorder.
Via
Investor's Business Daily
These stocks are moving in today's pre-market session
October 20, 2025
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via
Chartmill
RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria
October 20, 2025
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
October 20, 2025
Via
Benzinga
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
September 29, 2025
RAPT on track to initiate trial this year
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
October 19, 2025
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
August 27, 2025
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Reports Second Quarter 2025 Financial Results
August 07, 2025
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
There are notable gap-ups and gap-downs in today's session.
July 15, 2025
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session.
Via
Chartmill
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
June 23, 2025
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
June 13, 2025
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position
June 05, 2025
Clear Street’s initiated with a $3 price target, highlighting RPT904b as a “potentially best-in-class anti-IgE antibody.”
Via
Stocktwits
Topics
ETFs
12 Health Care Stocks Moving In Thursday's After-Market Session
June 05, 2025
Via
Benzinga
RAPT Therapeutics to Participate in Upcoming Investor Conferences
June 04, 2025
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
May 27, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
May 23, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
May 16, 2025
Via
Benzinga
RAPT Therapeutics Reports First Quarter 2025 Financial Results
May 08, 2025
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
April 15, 2025
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics to Participate in Upcoming Investor Conferences
March 07, 2025
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
March 06, 2025
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 09, 2025
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
January 06, 2025
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Futures Slide As Bond Yields Jump To 6 Month High
December 26, 2024
US stock futures and Treasuries dropped as muted trading resumed after the Christmas holiday, with investors looking to initial jobless claims data and a government bond auction later on Thursday.
Via
Talk Markets
Topics
Bonds
Commodities
Cryptocurrencies
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 26, 2024
Via
Benzinga
This Progressive Analyst Turns Bullish; Here Are Top 3 Upgrades For Thursday
December 26, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 23, 2024
Via
Benzinga
Why RAPT Therapeutics Stock Gained Over 100% On Monday?
December 23, 2024
RAPT Therapeutics partners with Shanghai Jemincare to develop RPT904, a potential alternative to Xolair, for food allergies. $35M upfront payment.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.